PMID- 36611131
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20230111
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Jan 7
TI  - Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with 
      tripe-negative breast cancer: exploratory analysis of real-world, multicenter 
      data.
PG  - 29
LID - 10.1186/s12885-023-10515-z [doi]
LID - 29
AB  - PURPOSE: Despite the poor prognosis of triple-negative breast cancer (TNBC), it 
      has been demonstrated that neoadjuvant immunotherapy in combination with 
      chemotherapy can improve the pathologic complete response (pCR) rate and/or 
      long-term outcome of TNBC. However, there have been no real-world studies 
      reporting on the effectiveness of neoadjuvant checkpoint inhibitors in early 
      TNBC. METHODS: Between November 2019 and December 2021, 63 early TNBC patients 
      treated with anti-PD-1 antibodies (pembrolizumab or camrelizumab) or anti-PD-L1 
      antibody (atezolizumab) in combination with chemotherapy at seven institutions 
      were included. PCR1 defined as ypT0/Tis and ypN0 was the primary endpoint. 
      Secondary endpoints included pCR2 defined as ypT0/Tis, overall response rate 
      (ORR), disease-free survival (DFS), drug-related adverse events (AEs) and 
      biomarkers. RESULTS: Among the patients in the current study, 34.9% of patients 
      were able to achieve pCR1, and 47.6% of patients had achieved pCR2. The ORR was 
      82.5%. 33 patients with non-pCR2 tumors were found to have a median DFS of 
      20.7 months (95% CI 16.3 months-not reached). The DFS of patients with pCR2 and 
      non-pCR2 after neoadjuvant therapy was significantly different (HR = 0.28, 95% CI 
      0.10-0.79; P = 0.038). The most common AEs were nausea (63.4%), fatigue (42.7%), 
      leucopenia (30.0%) and elevated transaminase (11.7%). CONCLUSION: It is possible 
      to achieve a meaningful pCR rate and DFS by combining neoadjuvant checkpoint 
      blockade with chemotherapy in patients with high-risk TNBC. Compared to clinical 
      trials, however, there was a slightly lower pCR rate in this multicentered 
      real-world study.
CI  - (c) 2023. The Author(s).
FAU - Deng, Heran
AU  - Deng H
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Yanjiang West Road 107#, Guangzhou, 510120, Guangdong, China.
FAU - Wang, Liying
AU  - Wang L
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Yanjiang West Road 107#, Guangzhou, 510120, Guangdong, China.
FAU - Wang, Na
AU  - Wang N
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Sun Yat-Sen 
      University, Dongfeng Road 651#, Guangzhou, 510060, Guangdong, China.
FAU - Zhang, Kejin
AU  - Zhang K
AD  - Xiangya Hospital of Central South University, Center South University, Changsha, 
      Hunan, China.
FAU - Zhao, Yanxia
AU  - Zhao Y
AD  - Union Hospital Tongji Medical College Huazhong University of Science and 
      Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
FAU - Qiu, Pengfei
AU  - Qiu P
AD  - Shandong Tumor Hospital, Shandong university, Jinan, Shandong, China.
FAU - Qi, Xiaowei
AU  - Qi X
AD  - The Southwest Hospital of AMU, Army Medical University, Chongqing, Sichuan, 
      China.
FAU - Zhang, Danhua
AU  - Zhang D
AD  - The Second Xiangya Hospital of Central South University, Center South University, 
      Changsha, Hunan, China.
FAU - Xu, Fei
AU  - Xu F
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-Sen University Cancer Center, Sun Yat-Sen 
      University, Dongfeng Road 651#, Guangzhou, 510060, Guangdong, China. 
      xufei@sysucc.org.cn.
FAU - Liu, Jieqiong
AU  - Liu J
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen 
      University, Yanjiang West Road 107#, Guangzhou, 510120, Guangdong, China. 
      liujieqiong01@163.com.
LA  - eng
GR  - 2021A1515011811/Natural Science Foundation of Guangdong Province/
GR  - 2022A1515012238/Natural Science Foundation of Guangdong Province/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230107
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Humans
MH  - *Triple Negative Breast Neoplasms/pathology
MH  - Neoadjuvant Therapy
MH  - Disease-Free Survival
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC9826585
OTO - NOTNLM
OT  - Anti-PD-1/L1 antibody
OT  - Neoadjuvant immunotherapy
OT  - Real-world study
OT  - Tripe-negative breast cancer
COIS- All authors have no competing interest.
EDAT- 2023/01/08 06:00
MHDA- 2023/01/11 06:00
PMCR- 2023/01/07
CRDT- 2023/01/07 23:22
PHST- 2022/08/08 00:00 [received]
PHST- 2023/01/05 00:00 [accepted]
PHST- 2023/01/07 23:22 [entrez]
PHST- 2023/01/08 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2023/01/07 00:00 [pmc-release]
AID - 10.1186/s12885-023-10515-z [pii]
AID - 10515 [pii]
AID - 10.1186/s12885-023-10515-z [doi]
PST - epublish
SO  - BMC Cancer. 2023 Jan 7;23(1):29. doi: 10.1186/s12885-023-10515-z.